| Related Information: |
| Australia: Important safety information for Janus kinase (JAK) inhibitors (Engli... 上载于 2023-05-11 |
| The United Kingdom: Janus kinase (JAK) inhibitors: new measures to reduce risks ... 上载于 2023-04-27 |
| 中国：国家药监局关于修订托法替布制剂说明书的公告（2023年第51号） 上载于 2023-04-25 |
| European Union: EMA confirms measures to minimise risk of serious side effects w... 上载于 2023-01-28 |
| Singapore: Janus Kinase (JAK) inhibitors and risk of major adverse cardiovascula... 上载于 2022-12-14 |
| Singapore: Risk of major adverse cardiovascular events, malignancy, thrombosis a... 上载于 2022-11-18 |
| European Union: EMA confirms measures to minimise risk of serious side effects w... 上载于 2022-11-12 |
| Canada: Canadian labelling for all JAK inhibitors to include risks of serious he... 上载于 2022-11-02 |
| EMA recommends measures to minimise risk of serious side effects with Janus kina... 上载于 2022-10-31 |
| European Union: EMA recommends measures to minimize risk of serious side effects... 上载于 2022-10-29 |
| Canada: Summary Safety Review - Xeljanz/Xeljanz XR (tofacitinib), Olumiant (bari... 上载于 2022-09-17 |
| European Union: EMA starts safety review of Janus kinase inhibitors for inflamma... 上载于 2022-02-12 |
| Canada: Safety review found a link between the use of Xeljanz／Xeljanz XR (tofaci... 上载于 2022-01-13 |
| The United States: FDA requires warnings about increased risk of serious heart-r... 上载于 2021-09-02 |
| The United States: Initial safety trial results find increased risk of serious h... 上载于 2021-02-05 |
| Singapore: Risk of venous thromboembolism with tofacitinib (English only) 上载于 2020-09-19 |
| Canada: Summary Safety Review - Xeljanz and Xeljanz XR (tofacitinib) and Jakavi ... 上载于 2020-06-19 |
| The United Kingdom: Tofacitinib (Xeljanz▼): new measures to minimise risk of ven... 上载于 2020-03-19 |
| The United Kingdom: Baricitinib (Olumiant▼): risk of venous thromboembolism (Eng... 上载于 2020-03-19 |
| Canada: XELJANZ ／ XELJANZ XR (tofacitinib) : Risk of thrombosis (English only) 上载于 2019-12-03 |
| European Union: Xeljanz to be used with caution for all patients at high risk of... 上载于 2019-11-16 |
| European Union: Xeljanz to be used with caution for all patients at high risk of... 上载于 2019-11-01 |
| Australia: Tofacitinib: Update - Warning about increased risks of blood clots an... 上载于 2019-10-16 |
| Xeljanz, Xeljanz XR (tofacitinib): Drug Safety Communication - Due to an Incread... 上载于 2019-07-29 |
| United States: Xeljanz, Xeljanz XR (tofacitinib): Drug Safety Communication - Du... 上载于 2019-07-27 |
| European Union: Restrictions in use of Xeljanz while EMA reviews risk of blood c... 上载于 2019-05-18 |
| The United Kingdom: Tofacitinib (Xeljanz): restriction of 10 mg twice-daily dose... 上载于 2019-05-18 |
| European Union: Increased risk of blood clots in lungs and death with higher dos... 上载于 2019-03-21 |
| Australia: Tofacitinib: clinical study finds increased risk of blood clots in th... 上载于 2019-03-21 |
| Canada: Clinical trial finds an increased risk of blood clots in the lungs and o... 上载于 2019-03-16 |
| The United States: Safety trial finds risk of blood clots in the lungs and death... 上载于 2019-02-26 |
